Table 2.
Changes in biochemical and non-invasive tests before and after the outbreak of the COVID-19 pandemic.
| Overall, n = 354 |
Without prior decompensations, n = 271 |
With prior decompensations, n = 83 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-pandemic | Pandemic | p value | Pre-pandemic | Pandemic | p value | Pre-pandemic | Pandemic | p value | |
| Platelets (109/L) | 143 (68) | 138 (67) | 0.02 | 152 (70) | 148 (68) | 0.13 | 111 (50) | 103 (50) | 0.16 |
| INR | 1.15 (0.25) | 1.17 (0.38) | 0.33 | 1.14 (0.27) | 1.14 (0.35) | 0.94 | 1.19 (0.17) | 1.27 (0.44) | 0.07 |
| Glucose (mg/dl) | 141.1 (60.9) | 146.7 (65.9) | 0.25 | 143.9 (66.8) | 148.3 (71.7) | 0.48 | 132.5 (37.3) | 142.1 (44.8) | 0.19 |
| Creatinine (mg/dl) | 0.91 (0.47) | 0.96 (0.57) | 0.002 | 0.87 (0.35) | 0.91 (0.48) | 0.042 | 1.06 (0.73) | 1.16 (0.79) | 0.004 |
| Bilirubin (mg/dl) | 0.94 (0.55) | 1.06 (1.21) | 0.022 | 0.86 (0.48) | 0.91 (0.53) | 0.019 | 1.22 (0.69) | 1.63 (1.34) | 0.09 |
| AST (U/L) | 38.7 (17.8) | 39.3 (22.2) | 0.61 | 38.0 (17.5) | 37.8 (18.9) | 0.82 | 41.3 (18.7) | 44.7 (31.0) | 0.35 |
| ALT (U/L) | 34.7 (22.8) | 33.4 (22.7) | 0.32 | 35.2 (21.3) | 33.4 (21.0) | 0.14 | 33.2 (27.8) | 33.3 (28.4) | 0.98 |
| Total CT (mg/dl) | 166.3 (39.1) | 168.1 (41.6) | 0.3 | 168.0 (38.9) | 171.4 (39.8) | 0.054 | 159.9 (39.4) | 155.8 (45.9) | 0.41 |
| HDL (mg/dl) | 49.5 (17.2) | 51.0 (17.9) | 0.24 | 49.3 (17.4) | 51.4 (17.9) | 0.09 | 51.6 (15.5) | 47.6 (18.1) | 0.34 |
| LDL (mg/dl) | 92.8 (34.8) | 92.9 (34.0) | 0.95 | 92.9 (33.9) | 93.3 (33.3) | 0.82 | 92.4 (42.5) | 90.0 (39.8) | 0.84 |
| Triglycerides (mg/dl) | 141.5 (94.8) | 142.1 (85.9) | 0.88 | 147.3 (100.4) | 150.7 (92.0) | 0.47 | 120.1 (66.8) | 110.3 (46.3) | 0.13 |
| Albumin (g/dl) | 4.10 (0.52) | 4.07 (0.58) | 0.14 | 4.20 (0.48) | 4.17 (0.53) | 0.25 | 3.76 (0.53) | 3.71 (0.64) | 0.36 |
| FIB-4 score | 4.16 (2.93) | 4.57 (3.82) | 0.003 | 3.72 (2.51) | 4.00 (3.29) | 0.047 | 5.74 (3.71) | 6.64 (4.79) | 0.026 |
| MELD score | 7.67 (3.00) | 8.16 (4.01) | 0.001 | 7.36 (2.70) | 7.55 (3.11) | 0.12 | 8.77 (3.69) | 10.35 (5.77) | 0.001 |
| Liver stiffness (kPa)∗ | 22.3 (13.5) | 22.8 (16.6) | 0.84 | ||||||
| CAP (dB/m)∗∗ | 315.0 (61.8) | 293.8 (85.2) | 0.14 | ||||||
Data are presented as mean (SD). Continuous variables were compared using paired t tests or the Wilcoxon matched-pairs signed-rank test, according to the normality of their distribution. On the other hand, categorical variables were compared by performing tests on the equality of proportions. A p <0.05 was considered statistically significant.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; CT: cholesterol; FIB, Fibrosis-4; INR, international normalized ratio; MELD, model for end-stage liver disease.
∗
Data available in 35 individuals.
∗∗
Data available in 30 individuals.